Sally Zhao

Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection.

John F. Flaherty, G. Foster, K. Agarwal, 2015, Journal of hepatology.

Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial

S. Vermeire, T. Hibi, G. Rogler, 2021, The Lancet.

A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn’s Disease

C. Siegel, E. Loftus, M. McKevitt, 2018, Journal of Crohn's & colitis.

PMO-31 Rapidity of ulcerative colitis symptom improvements during filgotinib induction: phase 2b/3 SELECTION study post-hoc analysis

J Zhang, T. Hibi, G. Rogler, 2021, Posters.

Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease

W. Sandborn, S. Danese, C. Randall, 2018, Journal of Crohn's & colitis.

Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects

Imad Hanna, S. Rebello, V. Jarugula, 2012, European Journal of Clinical Pharmacology.

Efficacy and Safety of Filgotinib as Induction Therapy for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the Phase 2b/3 SELECTION Study

S. Vermeire, T. Hibi, G. Rogler, 2021, Zeitschrift für Gastroenterologie.